7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Current knowledge of buprenorphine and its unique pharmacological profile.

      Pain practice : the official journal of World Institute of Pain

      Analgesics, Opioid, pharmacology, therapeutic use, Animals, Buprenorphine, Dose-Response Relationship, Drug, Female, Humans, Hyperalgesia, drug therapy, Hypothalamo-Hypophyseal System, drug effects, Immune System, Kidney Diseases, chemically induced, Male, Pituitary-Adrenal System, Psychomotor Performance, Randomized Controlled Trials as Topic, Respiratory Insufficiency, Transdermal Patch

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Despite the increasing clinical use of transdermal buprenorphine, questions have persisted about the possibility of a ceiling effect for analgesia, its combination with other μ-opioid agonists, and the reversibility of side effects. In October 2008, a consensus group of experts met to review recent research into the pharmacology and clinical use of buprenorphine. The objective was to achieve consensus on the conclusions to be drawn from this work. It was agreed that buprenorphine clearly behaves as a full μ-opioid agonist for analgesia in clinical practice, with no ceiling effect, but that there is a ceiling effect for respiratory depression, reducing the likelihood of this potentially fatal adverse event. This is entirely consistent with receptor theory. In addition, the effects of buprenorphine can be completely reversed by naloxone. No problems are encountered when switching to and from buprenorphine and other opioids, or in combining them. Buprenorphine exhibits a pronounced antihyperalgesic effect that might indicate potential advantages in the treatment of neuropathic pain. Other beneficial properties are the compound's favorable safety profile, particularly in elderly patients and those with renal impairment, and its lack of effect on sex hormones and the immune system. The expert group agreed that these properties, as well as proven efficacy in severe pain and favorable tolerability, mean that buprenorphine can be considered a safe and effective option for treating chronic cancer and noncancer pain. © 2010 World Institute of Pain.

          Related collections

          Author and article information

          Journal
          20492579
          10.1111/j.1533-2500.2010.00378.x

          Comments

          Comment on this article